European Burn Journal, Volume 3, Issue 4

Background: Procedural pain in burn patients continues to be a major problem. Frequently used analgesics, such as opioids, may have various side effects, including respiratory depression, nausea, and vomiting. Inhaled methoxyflurane has been used in...

Abstracts of the workshops, plenary sessions, oral and poster presentations of the 19th EBA Congress in Turin, Italy, 7–10 September 2022.

NovoSorb® Biodegradable Temporising Matrix (BTM) is a synthetic matrix used as an adjunct in the reconstruction of certain complex wounds. We present a gentleman who sustained severe full-thickness lower limb burns as a child which were treated w...

Early management of burns is an essential component of achieving desirable patient outcomes. One of the earliest points of patient management in the case of burn injuries is in the prehospital setting. Unlike first aid, which can be provided by a non...

Cellular therapies for burn wound healing, including the administration of mesenchymal stem or stromal cells (MSCs), have shown promising results. This review aims to provide an overview of the current administration methods in preclinical and clinic...

A burn injury affects a person’s health-related quality of life (HRQoL) in different ways and might influence their daily life for months and years afterward. The aim of this study was to examine how activity performance and subjective scar est...

Background: The incidence of sunburn injuries continues to rise despite increased awareness of the risks of sun exposure and availability of sun protection. Whilst not a significant burden on burns care services, patients remain exposed to associated...